The Kilkenny, Ireland facility will focus on the global manufacturing of sensors for Abbott’s CGM diabetes devices.

More than 800 people will be employed at the plant, which will make more Libre sensors than any of the company’s other facilities.

Wearable diagnostics are poised to transform subjective, episodic measures of disease progression to quantified, continuous data streams, according to some industry experts.